Skip to content
Screener

Integra LifeSciences IART Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Globus Medical logo
Globus MedicalGMED
$429.85M+36.7%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
Axogen logo
AxogenAXGN
ClearPoint Neuro logo
ClearPoint NeuroCLPT
MiMedx Group logo
MiMedx GroupMDXG
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.34B+35.1%
Enterprise value$3.09B+15.4%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Dollars in thousandsWeighted Average LifeCostAccumulated AmortizationNet
Completed technology17 years$1,480,641$(675,832)$804,809
Customer relationships12 years168,759(147,184)21,575
Trademarks/brand names27 years102,732(49,668)53,064
Codman tradenameIndefinite178,143178,143
Supplier relationships30 years30,211(20,593)9,618
All other6 years23,286(14,953)8,333
$1,983,772$(908,230)$1,075,542

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's finite-lived intangible assets, accumulated amortization?
Integra LifeSciences (IART) reported finite-lived intangible assets, accumulated amortization of $908.23M in Q2 2026.
How has Integra LifeSciences's finite-lived intangible assets, accumulated amortization changed year-over-year?
Integra LifeSciences's finite-lived intangible assets, accumulated amortization increased by 12.9% year-over-year, from $804.1M to $908.23M.
What is the long-term trend for Integra LifeSciences's finite-lived intangible assets, accumulated amortization?
Over 5 years (2020 to 2025), Integra LifeSciences's finite-lived intangible assets, accumulated amortization has grown at a 14.7% compound annual growth rate (CAGR), from $431.65M to $858.07M.

Ask your AI about Integra LifeSciences's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude